prasugrel (effient) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed under the brand name EFFIENT in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.   NCATS

Chemistry

  • SMILES: CC(=O)Oc1cc2CN(CCc2s1)C(C(=O)C3CC3)c4ccccc4F
  • InChIKey: DTGLZDAWLRGWQN-UHFFFAOYSA-N
  • Mol. Mass: 373.45
  • ALogP: 3.89
  • ChEMBL Molecules:
    prasugrel  
    prasugrel hydrochloride  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$0.2163 - $15.3771
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

cs-747 | effient | efient | ly640315 | prasugel | prasugrel | prasugrel hcl | prasugrel hydrochloride

Organizations (172)

Research & Development (160)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (58)

Approved Indications (2)


 

Acute Coronary Syndrome

Cardiovascular Diseases (approved 2009)

Experimental Indications - Clinical Trial Phases 1-4 (58)


 

Acute Coronary Syndrome (Phase 4)

Anemia, Sickle Cell (Phase 3)

Angina Pectoris (Phase 4)

Angina, Stable (Phase 4)

Angina, Unstable (Phase 4)

Angioplasty (Phase 4)

Angioplasty, Balloon, Coronary (Phase 4)

Asthma (Phase 4)

Atherosclerosis (Phase 2)

Atrial Fibrillation (Phase 4)

Blood Platelet Disorders (Phase 4)

Blood Platelets (Phase 4)

Cardiovascular Diseases (Phase 4)

Chest Pain (Phase 4)

Coronary Artery Bypass (Phase 3)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Coronary Restenosis (Phase 4)

Coronary Stenosis (Phase 4)

COVID-19 (Phase 3)

Critical Illness (Phase 2)

Death (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Embolism (Phase 4)

Endothelium (Phase 4)

Endovascular Procedures (Phase 4)

Foramen Ovale, Patent (Phase 3)

Fractional Flow Reserve, Myocardial (Phase 4)

Healthy Volunteers (Phase 4)

Heart Diseases (Phase 4)

Heart Failure, Systolic (Phase 4)

Hemorrhage (Phase 4)

HIV (Phase 1)

Hypothermia, Induced (Phase 4)

Infarction (Phase 4)

Intracranial Aneurysm (Phase 4)

Ischemia (Phase 4)

Ischemic Stroke (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 3)

Lung Diseases (Phase 4)

Migraine Disorders (Phase 3)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 4)

Non-ST Elevated Myocardial Infarction (Phase 4)

Percutaneous Coronary Intervention (Phase 4)

Pharmacokinetics (Phase 1)

Platelet Aggregation Inhibitors (Phase 4)

Prostheses and Implants (Phase 3)

Renal Dialysis (Phase 3)

Sepsis (Phase 4)

ST Elevation Myocardial Infarction (Phase 4)

Stents (Phase 2)

Stroke (Phase 4)

Thrombosis (Phase 4)

Vascular Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 164
  • # of Trial Organizations: 160

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue